Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
22 août 2024 07h31 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
08 août 2024 07h00 HE
|
Cognition Therapeutics, Inc.
- Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple Cognitive and Functional Measures - - On Track to...
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
05 août 2024 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders (the...
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
29 juil. 2024 07h00 HE
|
Cognition Therapeutics, Inc.
- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo -- Consistent Positive Changes Across Cognitive and Functional Measures -- Favorable Safety Profile with Most...
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
26 juil. 2024 16h11 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
02 juil. 2024 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
21 mai 2024 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
07 mai 2024 07h30 HE
|
Cognition Therapeutics, Inc.
- Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected Mid-2024 -- SHIMMER Study in Dementia with Lewy Bodies Completed Enrollment of 130 Participants - PURCHASE, N.Y., May 07,...
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
29 avr. 2024 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
22 avr. 2024 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...